INT48270

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1994
Last Reported 2009
Negated 1
Speculated 0
Reported most in Abstract
Documents 44
Total Number 44
Disease Relevance 21.31
Pain Relevance 6.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (RNF130) ligase activity (RNF130) cytoplasm (RNF130)
Anatomy Link Frequency
platelet 21
7E3 2
coronary artery 1
femoral artery 1
RNF130 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 14 100.00 Very High Very High Very High
ischemia 12 99.92 Very High Very High Very High
aspirin 35 99.42 Very High Very High Very High
Angina 83 99.24 Very High Very High Very High
Percutaneous transluminal coronary angioplasty 4 97.04 Very High Very High Very High
agonist 4 75.00 Quite High
Serotonin 1 71.52 Quite High
5HT 3 70.64 Quite High
adenocard 2 69.20 Quite High
Onset of action 2 66.16 Quite High
Disease Link Frequency Relevance Heat
Coronary Artery Disease 18 99.92 Very High Very High Very High
Syndrome 16 99.66 Very High Very High Very High
Cv General 3 Under Development 78 99.24 Very High Very High Very High
Death 33 99.00 Very High Very High Very High
Thrombosis 17 98.92 Very High Very High Very High
Cv Unclassified Under Development 10 98.70 Very High Very High Very High
Myocardial Infarction 78 98.60 Very High Very High Very High
Acute Coronary Syndrome 68 98.02 Very High Very High Very High
Atherosclerosis 2 97.92 Very High Very High Very High
Stable Angina Pectoris 4 97.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Several patient subgroups appear to benefit preferentially from inhibition of platelet glycoprotein (GP) IIb/IIa receptors.
Negative_regulation (inhibition) of GP in platelet
1) Confidence 0.57 Published 1998 Journal Am. J. Cardiol. Section Abstract Doc Link 9551595 Disease Relevance 0.24 Pain Relevance 0
The era of platelet glycoprotein (GP) IIb/IIIa receptor inhibition in cardiology was inaugurated in 1994 with the publication of the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial results.
Negative_regulation (inhibition) of GP in 7E3
2) Confidence 0.57 Published 1998 Journal Eur. Heart J. Section Abstract Doc Link 9597518 Disease Relevance 0.32 Pain Relevance 0.07
More recently developed agents, such as low-molecular-weight heparins (LMWHs), glycoprotein (GP) IIb-IIIa inhibitors, direct thrombin inhibitors, Factor Xa inhibitors and thienopyridines, offer several potential advantages, either as an alternative to unfractionated heparin (i.e., LMWHs) or as an add-on therapy to aspirin and unfractionated heparin (or LMWHs; e.g., GP IIb-IIIa inhibitors, thienopyridines).
Negative_regulation (inhibitors) of GP associated with aspirin
3) Confidence 0.57 Published 2003 Journal Expert Opin Investig Drugs Section Abstract Doc Link 14640941 Disease Relevance 0.71 Pain Relevance 0.13
Selective inhibition of the platelet glycoprotein (GP) IIb/ IIIa surface receptor is a potent mechanism to inhibit platelet aggregation and thrombus formation.
Negative_regulation (inhibition) of GP in platelet associated with thrombosis
4) Confidence 0.57 Published 1998 Journal Am. J. Cardiol. Section Abstract Doc Link 9809890 Disease Relevance 0.25 Pain Relevance 0.04
Like barbourin, eptifibatide is a specific and robust inhibitor of the GP IIb-IIIa receptor function, having a low affinity for other integrins and strongly preventing platelet aggregation.
Negative_regulation (inhibitor) of GP in platelet
5) Confidence 0.57 Published 1997 Journal Am. J. Cardiol. Section Abstract Doc Link 9291241 Disease Relevance 0.40 Pain Relevance 0.03
Stents were placed in 79% of patients treated with GP IIb/IIIa inhibitors.
Negative_regulation (inhibitors) of GP
6) Confidence 0.42 Published 2003 Journal Am. J. Cardiol. Section Abstract Doc Link 12686333 Disease Relevance 0.54 Pain Relevance 0.10
CONCLUSIONS: These observations confirm the immediate beneficial effects of platelet GP IIb/IIIa blockade with abciximab in acute ischemic syndromes and suggest that improvement of microvascular function may play a central role in the mechanism of action of this drug.


Negative_regulation (blockade) of GP in platelet
7) Confidence 0.42 Published 2002 Journal J. Am. Coll. Cardiol. Section Body Doc Link 12505220 Disease Relevance 0 Pain Relevance 0
Eptifibatide (Integrilin) is a selective inhibitor of platelet glycoprotein (GP) IIb/IIIa receptors used as adjunctive therapy for patients undergoing percutaneous coronary intervention (PCI) and for patients with acute coronary syndromes (ACS), particularly those requiring PCI.
Negative_regulation (inhibitor) of GP in platelet associated with acute coronary syndrome
8) Confidence 0.42 Published 2003 Journal Pharmacoeconomics Section Abstract Doc Link 12908844 Disease Relevance 0.32 Pain Relevance 0.06
With enrollment of almost 11,000 patients, not only is the PURSUIT trial the largest trial of a GP IIb-IIIa inhibitor to date, but it is also the largest clinical study ever conducted in patients with non-ST-segment elevation ACS.
Negative_regulation (inhibitor) of GP associated with acute coronary syndrome
9) Confidence 0.42 Published 2000 Journal Clin Cardiol Section Abstract Doc Link 11019716 Disease Relevance 0.64 Pain Relevance 0.09
Trials of newer oral GP IIb/IIIa inhibitors are under way or are planned.
Negative_regulation (inhibitors) of GP
10) Confidence 0.42 Published 2001 Journal Cerebrovasc. Dis. Section Abstract Doc Link 11316919 Disease Relevance 0.66 Pain Relevance 0.42
The purpose of this study was to compare the effects of two different LMWHs, enoxaparin and nadroparin, accompanied by platelet GP IIb/IIIa inhibition on MACE in high-risk unstable angina.
Negative_regulation (inhibition) of GP in platelet associated with angina
11) Confidence 0.42 Published 2003 Journal Jpn Heart J Section Abstract Doc Link 14711185 Disease Relevance 0.86 Pain Relevance 0.45
The role of long-term treatment with oral platelet GP IIb/IIIa receptor inhibitors in patients with coronary artery disease is unproven.
Negative_regulation (inhibitors) of GP in platelet associated with coronary artery disease
12) Confidence 0.42 Published 2003 Journal Am J Cardiovasc Drugs Section Abstract Doc Link 14727937 Disease Relevance 0.37 Pain Relevance 0.27
This study examined the dose-response effect on inhibition of platelet aggregation by roxifiban (DMP754), a novel oral platelet GP IIb/IIIa receptor inhibitor, and its safety and tolerability in patients with a history of chronic stable angina pectoris.
Negative_regulation (inhibitor) of GP in platelet associated with stable angina pectoris and angina
13) Confidence 0.42 Published 2003 Journal Am J Cardiovasc Drugs Section Abstract Doc Link 14727937 Disease Relevance 0.44 Pain Relevance 0.27
Thus, roxifiban appears to be a potent oral platelet GP IIb/IIIa receptor inhibitor that is clinically well-tolerated and deserves further study as a new treatment strategy in patients with chronic stable angina pectoris.


Negative_regulation (inhibitor) of GP in platelet
14) Confidence 0.42 Published 2003 Journal Am J Cardiovasc Drugs Section Body Doc Link 14727937 Disease Relevance 0 Pain Relevance 0
A prospective nonrandomized single-center pilot study of the StarClose device included a subset of patients undergoing percutaneous coronary intervention utilizing GP IIb/IIIa inhibitors.
Negative_regulation (inhibitors) of GP
15) Confidence 0.42 Published 2005 Journal Catheter Cardiovasc Interv Section Abstract Doc Link 16152652 Disease Relevance 0.16 Pain Relevance 0.05
The aim of the study was to determine the safety and efficacy of a novel femoral artery closure device (StarClose, Abbott Vascular Devices, Redwood City, CA) following percutaneous coronary intervention employing aspirin, heparin, and glycoprotein (GP) IIb/IIIa inhibition.
Negative_regulation (inhibition) of GP in femoral artery associated with aspirin
16) Confidence 0.42 Published 2005 Journal Catheter Cardiovasc Interv Section Abstract Doc Link 16152652 Disease Relevance 0.13 Pain Relevance 0.05
We prospectively surveyed the indications, frequency, and complications associated with the use of GP IIb/IIIa inhibitors in percutaneous coronary intervention in a tertiary center setting.
Negative_regulation (inhibitors) of GP
17) Confidence 0.42 Published 2006 Journal Cardiovascular revascularization medicine : including molecular interventions Section Abstract Doc Link 17174871 Disease Relevance 0.64 Pain Relevance 0.05
The ACUITY study suggests that bivalirudin plus a GP IIb/IIIa inhibitor is a suitable alternative to standard therapy for moderate- to high-risk patients with non-ST-segment elevation ACS who are undergoing early invasive intervention, and bivalirudin alone may be preferred because of a lower risk of major bleeding.
Negative_regulation (inhibitor) of GP
18) Confidence 0.42 Published 2007 Journal Am J Health Syst Pharm Section Body Doc Link 17519441 Disease Relevance 0.07 Pain Relevance 0
There was no significant reduction in death (OR, 0.87; 95% CI, 0.73-1.03; P = 0.1), myocardial infarction (OR, 0.91; 95% CI, 0.82-1.004; P = 0.06), or refractory ischemia (OR, 0.92; 95% CI, 0.78-1.1; P = 0.36) in patients treated with GP IIb/IIIa inhibitors.
Neg (no) Negative_regulation (inhibitors) of GP associated with ischemia, myocardial infarction and death
19) Confidence 0.42 Published 2000 Journal Cardiovasc Drugs Ther Section Abstract Doc Link 10935147 Disease Relevance 1.08 Pain Relevance 0.32
These pilot study results support the concept that effective blockade of the platelet GPIIb/IIIa receptors can reduce myocardial infarction and facilitate PTCA in patients with refractory unstable angina.


Negative_regulation (blockade) of GP in platelet
20) Confidence 0.42 Published 1994 Journal Circulation Section Body Doc Link 7508826 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox